Wall Street Zen Upgrades IQVIA (NYSE:IQV) to “Buy”

by · The Cerbat Gem

IQVIA (NYSE:IQV – Get Free Report) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

Several other brokerages have also recently weighed in on IQV. UBS Group upped their price objective on shares of IQVIA from $250.00 to $280.00 and gave the stock a “buy” rating in a research note on Thursday, January 8th. Stifel Nicolaus increased their price target on IQVIA from $234.00 to $254.00 and gave the stock a “buy” rating in a research report on Wednesday, October 29th. Evercore ISI lifted their price objective on IQVIA from $220.00 to $240.00 and gave the company an “outperform” rating in a research report on Wednesday, October 8th. JPMorgan Chase & Co. raised their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.06.

Check Out Our Latest Stock Report on IQV

IQVIA Stock Up 1.7%

NYSE IQV opened at $239.28 on Friday. IQVIA has a twelve month low of $134.65 and a twelve month high of $247.04. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock has a market cap of $40.75 billion, a PE ratio of 32.82, a PEG ratio of 2.39 and a beta of 1.36. The firm has a 50-day simple moving average of $229.57 and a 200 day simple moving average of $206.73.

IQVIA (NYSE:IQV – Get Free Report) last posted its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The business had revenue of $4.10 billion for the quarter, compared to analysts’ expectations of $4.07 billion. During the same quarter in the previous year, the firm posted $2.84 earnings per share. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, research analysts forecast that IQVIA will post 10.84 EPS for the current year.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On IQVIA

Several institutional investors have recently bought and sold shares of IQV. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. increased its position in shares of IQVIA by 1,340.0% in the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its holdings in IQVIA by 219.6% during the third quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock worth $30,000 after acquiring an additional 101 shares in the last quarter. Measured Wealth Private Client Group LLC bought a new position in IQVIA in the third quarter valued at approximately $30,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of IQVIA during the 3rd quarter worth approximately $36,000. Institutional investors own 89.62% of the company’s stock.

About IQVIA

(Get Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Recommended Stories